Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI)



Sprung, Victoria S ORCID: 0000-0002-2666-4986, Kemp, Graham J ORCID: 0000-0002-8324-9666, Wilding, John Ph ORCID: 0000-0003-2839-8404, Adams, Valerie, Murphy, Kieran, Burgess, Malcolm, Emegbo, Stephen, Thomas, Matthew, Needham, Alexander J, Weimken, Andrew
et al (show 4 more authors) (2020) Randomised, cOntrolled Multicentre trial of 26 weeks subcutaneous liraglutide (a glucagon-like peptide-1 receptor Agonist), with or without contiNuous positive airway pressure (CPAP), in patients with type 2 diabetes mellitus (T2DM) and obstructive sleep apnoEa (OSA) (ROMANCE): study protocol assessing the effects of weight loss on the apnea-hypnoea index (AHI). BMJ OPEN, 10 (7).

Access the full-text of this item by clicking on the Open Access link.
Item Type: Article
Uncontrolled Keywords: sleep medicine, diabetes & endocrinology, protocols & guidelines
Depositing User: Symplectic Admin
Date Deposited: 10 Aug 2020 07:38
Last Modified: 05 Oct 2022 22:02
DOI: 10.1136/bmjopen-2020-038856
Open Access URL: https://bmjopen.bmj.com/content/10/7/e038856
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3096949